Tandem Diabetes Care, Inc. (TNDM) Q3 2026 earnings results
Tandem Diabetes Care, Inc. (TNDM) reported Q3 2026 results on Nov 5, 2026, 4:08:57 PM ET: GAAP EPS -$0.10 vs. -$0.24 expected (beat by 58.4%); revenue $283.69M vs. $265.85M expected (beat by 6.7%). Outlook: Full-year 2026 sales are estimated to be approximately $1.065 billion to $1.085 billion.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (GAAP, diluted) | -$0.10 | -$0.24 | Beat by 58.4% |
| Revenue | $283.69M | $265.85M | Beat by 6.7% |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Nov 5, 2026, 4:08:57 PM ET. Nexqual published them 119 seconds after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 13.8% from $249.25M; GAAP diluted EPS was -$0.10 vs. -$0.31 (+67.7%).
Stock reaction
The results came out after the market closed. TNDM closed at $16.91 on November 6, 2026, down 6.0% from its $17.99 close on November 5, 2026 before the results. Latest: $18.36 as of 11:40 AM ET, +2.1% since the pre-release close.
Questions and answers
Did Tandem Diabetes Care, Inc. beat earnings expectations?
Yes. Tandem Diabetes Care, Inc. reported GAAP EPS of -$0.10 against an average analyst estimate of -$0.24 (beat by 58.4%), and revenue of $283.69M against $265.85M expected (beat by 6.7%).
What were Tandem Diabetes Care, Inc.'s Q3 2026 earnings and revenue?
GAAP diluted EPS of -$0.10 and revenue of $283.69M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 13.8% from $249.25M; GAAP diluted EPS was -$0.10 vs. -$0.31 (+67.7%).
When did Tandem Diabetes Care, Inc. report Q3 2026 earnings?
Nov 5, 2026, 4:08:57 PM ET, in an SEC 8-K filing (Item 2.02).
How did TNDM stock react to the earnings?
The results came out after the market closed. TNDM closed at $16.91 on November 6, 2026, down 6.0% from its $17.99 close on November 5, 2026 before the results. Latest: $18.36 as of 11:40 AM ET, +2.1% since the pre-release close.
What did Tandem Diabetes Care, Inc. say about its outlook?
Full-year 2026 sales are estimated to be approximately $1.065 billion to $1.085 billion.
More on TNDM
TNDM stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings November 5, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built November 10, 2026 at 16:40 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 10, 2026 at 16:40 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt